A photo from Dr. Steve Woodle's presentation at the University of Arizona College of Medicine – Tucson on kindey transplant rejection.
The University of Cincinnati’s E. Steve Woodle, MD, will speak on “Innovative Approaches for Prevention and Treatment of Rejection: The Cincinnati Experience” in a special guest lecture hosted by the University of Arizona Division of Nephrology on Friday, April 20.
Dr. Woodle’s lecture will be noon-1 p.m. in the Chase Auditorium (Room 8403) at the UA College of Medicine – Tucson. It will be preceded by lunch from 11:30 a.m.-noon.
“Dr. Woodle is an international leader in antibody mediated rejection and steroid minimization protocols in kidney transplantation,” said Prabir Roy-Chaudhury, MD, PhD, UA nephrology chief and a professor of medicine. “We are excited to have him give this address.”
Click here or on the image at right to view, post and share the flyer for this event: 
neph-guest-speaker-dr.-steve-woodle_04-20-18_flyer.pdf
Dr. Woodle is a professor and the William A. Altemeier Chair in Surgery, director of the Division of Transplantation, and director of the Israel Penn Center for Transplant Tumor Registry in the Department of Surgery at the University of Cincinnati College of Medicine and UC Health in Cincinnati, Ohio.
EXTRA INFO
In addition to E. Steve Woodle, MD’s talk at the University of Arizona, those interested in immunosuppression drugs to help prevent organ rejection after transplant surgery might also want to attend an event Thursday, April 19, 6:30 p.m., at the restaurant Tavalino’s, 2870 E. Skyline Dr., across from La Encantada Mall.
The topic: “Take a Closer Look: A Unique Tacrolimus Treatment Option”
Speaking will be Rita R. Alloway, PharmD, a research professor in the Division of Nephrology and Hypertension, Transplantation Section, University of Cincinnati College of Medicine. Dr. Alloway is also the college’s director of transplant clinical research with dual appointments in nephrology and the Department of Surgery, Division of Transplant Surgery, and plays a similar role in both departments as director of the Transplant Specialty Pharmacy Residency and Fellowship Program. She was previously on faculty at the University of Tennessee – Memphis, where she earned her doctor of pharmacy degree. She did her general clinical residency at the VA Medical Center in Memphis and completed her immunotherapeutics traineeship at Vanderbilt University Medical Center, in Nashville, Tenn.
The event is hosted by Veloxis Pharmaceuticals Inc. (formerly LifeCycle Pharma), Horsholm, Denmark, maker of ENVARSUS XR®—a tacrolimus formulation or calcineurin-inhibitor immunosuppressant available for oral administration as extended-release tablets. Space is limited. Click here for the flyer for this event. RSVP today by contacting your local Veloxis transplant account manager: Michelle Miles, (303) 907-3868 or mmi@veloxis.com
Dr. Woodle received his undergraduate degree at Texas A&M University and his medical degree from the University of Texas Medical Branch at Galveston, afterwards completing fellowships in kidney and pancreas transplantation as well as liver transplantation and hepatobiliary surgery at the University of Chicago. He also was an NIH Surgical Research Fellow at both the University of California-Davis, where he completed his residency in general surgery, and at the University of Chicago.
He is a member of over 30 scientific and professional societies, including the American Surgical Association. He has chaired committees in the American Society of Transplantation and has served on the board of directors of the American Society of Transplantation.
Dr. Woodle has published over 300 scientific articles and 20 book chapters in the field of transplantation. He has received National institutes of Health research grants in immunobiology and a Clinician Scientist Research Award from the American Heart Association. In addition, he has served on several NIH study sections and U.S. Food and Drug Administration committees that regulate immunosuppressive drug approval. This includes trial design committees for a number of multicenter studies, and serving as lead investigator in several multicenter trials.
Dr. Woodle has made seminal contributions in the areas of immunosuppressive drug development, having introduced teplizumab and bortezomib as immunosuppressive agents in the transplant field. His research currently focuses on development of plasma cell targeted therapies, innovative immunosuppresion regimens with costimulatory blockade, corticosteroid elimination, kidney exchange programs and post-transplant malignancies.
His clinical activities focus on kidney transplantation, with particular emphasis on living donor kidney transplantation. He also initiated the Sensitized Patient Program and Clinics, which he currently continues to lead and staff at UC Health.
CONTACT: Stephanie Delgado, administrative associate, Division of Nephrology, 626-3956 or delgados1@deptofmed.arizona.edu